Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R41CA224830-01
Agency Tracking Number: R41CA224830
Amount: $299,975.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA16-303
Solicitation Year: 2016
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-07-03
Award End Date (Contract End Date): 2020-01-02
Small Business Information
6510 N CAMINO ARTURO, Tucson, AZ, 85718-2014
DUNS: 079416826
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (501) 296-1154
Business Contact
Phone: (847) 254-9842
Research Institution
NEW YORK, NY, 10065-4805
 Nonprofit college or university
ABSTRACTThe Aurora Kinase FamilyAKFcomprises heavily pursued therapeutic targets for cancer because of their intimate involvement in cell division and tumor progressionNumerous therapeutic campaigns have been initiated against the AKFwith promising clinical successes emanating from strategies targeting either Aurora A or Aurora BHoweverthe US Food and Drug Administration has yet to approve a cancer therapy that targets either Aurora A or BIn an attempt to identify a more viable Aurora B targeted agentwe have completed preliminarypre clinical development of a clinical candidateThe candidate represents the first Aurora B targeted agent that can be safely administered through an oral dose with statistically significantanti tumor efficacy observed atmg kg PO dosingThrough pre clinical studiesit was determined that the candidate is selective for oncogene driven cell lines and attains efficacy through Aurora B inhibitionThe candidate displayed broad activity against a variety of solid and liquid tumors attaining GIvalues aroundnMInterestinglythe candidate can potently block acute myeloid leukemiaAMLcell growth as exhibited through inhibition of the HLAML cell lineGInMbut does not inhibit normal hematopoietic progenitor cellsHSPCsImportantlypre clinical and clinical studies have identified AML as an exceptional candidate for Aurora B inhibition andaccordinglythe candidate has demonstrated immense potential to effectively treat AMLWe wish to further progress the clinical candidate for the AML indication because of activity in HLand MOLMAML cell lines and from the mounting pre clinical and clinical evidence that AML is extensively driven through Aurora B activityIn the following proposalwe will further develop the candidate by completing pilot formulationadditional AML efficacy studiesPK PDand toxicity studiesThis will acquire pivotal data necessary to justify completing an investigative new drugINDpackageWe have established a robust proof of concept data package for the compoundbut specific facets of preclinical development are lacking that warrant additional pre IND developmentWith the completion of this proposalwe will have a data package that will merit full IND development that will lead to eventual commercialization of the clinical candidate PROJECT NARRATIVEAn orally administered Aurora B inhibitor has been identified that can potentially offer acute myeloid leukemiaAMLpatients a more effective treatmentAdministration of the therapy has been considerably improved over previous treatmentsand the therapy is highly selective for malignant growthThe completion of the proposed research will help this breakthrough medicine reach AML patients quickly and safely

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government